A Study of Repotrectinib in Combination With Other Anticancer Therapies for the Treatment of Subjects With KRAS-Mutant Solid Tumors

Clinical trial NCT05071183 · TERMINATED

Trial details

NCT number: NCT05071183
Sponsor: Turning Point Therapeutics, Inc.
Status: TERMINATED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

KRAS Mutation-Related Tumors Metastatic Solid Tumor Advanced Solid Tumor

Start date: 2021-09-23
Primary completion: 2023-03-01
Enrollment: 9

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.